Raymond James Financial
NRIX icon

Raymond James Financial’s Nurix Therapeutics NRIX Stock Holding History

Raymond James Financial’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.2M Buy
+353,733
New +$5.87M ﹤0.01% 2559
2025
Q3 		– Sell
-1,618
Closed -$18.4K – 6127
2025
Q2 		$18.4K Buy
+1,618
New +$17.5K ﹤0.01% 5634
2025
Q1 		– Sell
-54,453
Closed -$1.03M – 4909
2024
Q4 		$1.03M Buy
+54,453
New +$1.25M ﹤0.01% 3435

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Raymond James Financial's NRIX Position: Q1 2026 in Review

Raymond James Financial opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 353,733 shares worth $5.2M. The stake represents ﹤0.01% of the portfolio and ranks #2559 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in NRIX as recently as Q2 2025.

Raymond James Financial first reported a position in NRIX in Q4 2024 and has held it in 3 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Raymond James Financial held 353,733 shares of Nurix Therapeutics worth $5.2M as of Q1 2026.
  • Nurix Therapeutics was a new Raymond James Financial position in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #2559 holding.
  • Raymond James Financial first reported a position in Nurix Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.